cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate · Gilead Sciences Inc · NDA 207561
Genvoya
Earliest generic entry, as listed
6 Apr 2033
Blocked by patent: US 10039718.
Listed patents · 17 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10039718 | — | 6 Apr 2033 |
| US 8754065 | — | 15 Feb 2033 |
| US 9296769 | — | 15 Feb 2033 |
| US 10039718 | product | 6 Oct 2032 |
| US 8754065 | substance, product, use U-257 | 15 Aug 2032 |
| US 9296769 | substance, product, use U-257 | 15 Aug 2032 |
| US 8633219 | — | 30 Oct 2030 |
| US 8633219 | product, use U-257 | 30 Apr 2030 |
| US 8148374 | — | 3 Mar 2030 |
| US 9891239 | — | 3 Mar 2030 |
| US 8148374 | substance, product, use U-1279 | 3 Sep 2029 |
| US 9891239 | product, use U-257 | 3 Sep 2029 |
| US 7635704 | — | 26 Apr 2027 |
| US 8981103 | — | 26 Apr 2027 |
| US 7176220 | — | 27 Feb 2027 |
| US 7635704 | substance, product, use U-257 | 26 Oct 2026 |
| US 8981103 | substance, product | 26 Oct 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207561 · 001 · RLD | tablet, oral | 150MG;150MG;200MG;EQ 10MG BASE | 6 Apr 2033 |
Expired or delisted (1)
- US 7176220 · substance, product, use U-257 · 27 Aug 2026